Keyword: Seventh Sense Biosystems
Genomics, bioelectronics and artificial intelligence are clear themes among FierceMedTech's 2017 Fierce 15 companies.
Seventh Sense Biosystems (7SBio) concentrates on revolutionizing blood collection with a device that is easy and painless to use.
When we were compiling this year’s crop of Fierce 15 companies, some clear themes stood out. Genomics. Bioelectronics. Artificial intelligence. But while multiple companies are working to improve the use of these technologies, there runs a deeper current: making care more accessible.
The deal connects Ionis to the manufacturer of a blood collection device that could simplify mitigation of its drugs’ safety risks.
Velano Vascular raised $17 million in financing, which it will put toward scaling and commercializing its line of vascular access devices.
The FDA cleared Velano Vascular’s second iteration of its needle-free blood draw device, which attaches to the peripheral IV line that most hospital patients already have.
Seventh Sense Biosystems picked up an FDA nod for its “push-button” blood collection device, specifically to test the HbA1c levels in patients with diabetes and prediabetes. The company plans to add more assays for use with the device.
Seventh Sense Biosystems picked up a $10 million Series C to develop new products around and to expand manufacturing capacity for its “push-button” blood collection device.